

Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes—Results from OASIS 1 and PIONEER PLUS Trial
In this medfyle
OASIS: in adults without type 2 diabetes with overweight or obesity, once daily oral semaglutide 50 mg led to superior and clinically meaningful decrease in body weight vs. placebo. PIONEER PLUS: in adults with inadequately controlled type 2 diabetes oral semaglutide 25 mg and 50 mg were superior to 14 mg in reducing HbA1c and body weight.
Expert commentary
About this Medfyle
This content is intended for an international audience of non-UK healthcare professionals. The content is made available through a licensing agreement between Infomedica and the American Diabetes Association (ADA).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the ADA.
©2023 Infomedica-Medfyle. All rights reserved.